Don Zhang

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd.. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Don Zhang. Retrieved from https://idiyas.com/inventor/don-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 76.5

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 13(Granted Patents)

Location History:

Old Lyme, CT (US) (2006)
Branford, CT (US) (2014 - 2015)
Plainsboro, NJ (US) (2016 - 2018)
Princeton, NJ (US) (2019 - 2022)

Company Filing History:

Beta Pharma (Shanghai) Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

EGFR Inhibitors

CDK Modulators

Pharmaceutical Formulations

Tyrosine Kinase Inhibitors

Indolinone Compounds

2-H-Indazole Derivatives

Anilinopyrimidine Derivatives

Organophosphorus Compounds

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595246 - Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof (2026-04-07),

2. 12390464 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors (2025-08-19),

3. 12258365 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof (2025-03-25),

4. 12187707 - Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof (2025-01-07),

5. 11414401 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2022-08-16),

6. 11352341 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof (2022-06-07),

7. 11180478 - Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof (2021-11-23),

8. 11052086 - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers (2021-07-06),

9. 10844045 - Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof (2020-11-24),

10. 10590111 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2020-03-17),

11. 10239864 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2019-03-26),

12. 9878994 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2018-01-30),

13. 9820721 - Aspiration and biopsy needle apparatus and devices and applications thereof (2017-11-21),

14. 9359370 - Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof (2016-06-07),

15. 9163010 - Indolinone protein kinase inhibitors (2015-10-20),

Title: The Innovator Extraordinaire: Don Zhang

Introduction:

Don Zhang, a prolific inventor based in Princeton, NJ, has made significant contributions to the field of pharmaceuticals and cancer research with a total of 13 patents under his belt.

Latest Patents:

Don Zhang's recent patents showcase his groundbreaking work in the development of novel pharmaceutical compounds. These include "Substituted 2-anilinopyrimidine derivatives as EGFR modulators" and "2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof". These inventions hold immense promise for the treatment and prevention of diseases mediated by epidermal growth factor receptors and cyclin-dependent kinases.

Career Highlights:

Having worked with esteemed companies such as Beta Pharma, Inc. and Beta Pharma (Shanghai) Co., Ltd., Don Zhang has established himself as a key figure in the pharmaceutical industry. His patents not only demonstrate his technical acumen but also his drive to improve healthcare outcomes.

Collaborations:

Throughout his career, Don Zhang has collaborated with esteemed colleagues like Jirong Peng and Michael Nicholas Greco. These partnerships have been instrumental in advancing his research and bringing innovative pharmaceutical solutions to the market.

Conclusion:

Don Zhang's innovative spirit and dedication to advancing healthcare make him a standout figure in the world of inventors. His pioneering work in developing pharmaceutical compounds underscores his commitment to improving the lives of those affected by various diseases.

Profile summary based on public USPTO records.